THE ROLE OF GLYCEMIA SELF-CONTROL IN DECREASE OF THE RISK OF DIABETIC MICROAND MACROANGIOPATHIES? BEST PRACTICE

Cover Page

Cite item

Full Text

Abstract

Combination of traditional cardiovascular risk factors with specific risk factors of early development and quick progression of atherosclerosis including first of all hyperglycemia is typical in patients with diabetes mellitus (DM). The results of large clinical trials ADVANCE, ACCORD and VADT definitely proved the role of glycemia control in prevention of microvascular complications of DM. In some studies it was proven that parameters of glycemic variability (GV) are significant in prognosing diabetic retinopathy, nephropathy and cardiovascular complications. The role of hyperglycemia in development of microvascular complication in patients with DM type 2 is not clear at present. Modern approach to DM management as one of the most important methods of micro and macroangiopathies prevention includes necessary glucose self-control. Glycemia self-control should be precise, easy and comfortable letting the patient to have effective and safe hypoglycemic therapy. Choice of glucometer is one of the main aspects of blood glucose self-control. From the point of view of the doctor the most important criteria for glucometer choice is its conformance to standards of accuracy, and from the patient’s point of view - its convenience and ease in use. Because of technological advancements the accuracy of blood glucose level test increases and the procedure of glycemia self-control becomes easier that results in increase of adherence to treatment and hypoglycemic therapy effectiveness. Achievement and sustenance of glycemia target level, prevention of micro and macroangio-pathic complications are impossible without full active participation of the patient in DM treatment and blood glucose self-control with the use of precise and convenient for the patient glucometer such as Contour Plus One.

About the authors

Galina A. Batrak

Ivanovo State Medical Academy

Email: gbatrak@mail.ru
д-р мед. наук, доц., проф. каф. терапии и эндокринологии Ivanovo, Russia

Svetlana E. Miasoedova

Ivanovo State Medical Academy

д-р мед. наук, проф., зав. каф. терапии и эндокринологии Ivanovo, Russia

Anna N. Brodovskaia

City Clinical Hospital №4

врач-эндокринолог Ivanovo, Russia

References

  1. Dedov II. Diabetes mellitus-a dangerous treat to the mankind. Vestn Ross Akad Med Nauk 2012; 1: 7-13.
  2. Auni G et al. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 2008; 31 (4): 714-9.
  3. Ruckert IM et al. Blood pressure and lipid management fall far short in persons with type 2diabe-tes: Results from the DIAB-CORE Consortium including six German population-based studies. Cardiovasc Diabetol 2012; 11 (1): 50.
  4. Pitocco D et al. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud 2010; 7 (1): 15-25.
  5. Kitasato L et al. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide. Cardiovasc Diabetol 2012; 11: 79.
  6. Radermecker RP et al. Blood glucose control and cardiovascular disease in patiens with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials. Rev Med Liege 2008; 63 (7-8). 511-8.
  7. Ginsberg HN et al. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. The Action to Control Cardiovascular Risk in Diabetes (ACCORD Study Group). N Engl J Med 2010; 18.
  8. Fuchtenbusch M, Hummel M. Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study, MMW. Fortschr Med 2008; 150 (17): 42-4.
  9. Cefalu WT, Watson K, Cefalu WT. Intensive glycemic control and cardiovascular disease. Observations from the ACCORD study. Diabetes 2008; 57: 1163-5.
  10. Patel A et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
  11. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й вып. М., 2019. @@Algorithms for specialized medical care for patients with diabetes mellitus. Ed. I.I.Dedov, M.V.Shestakova, A.Yu.Mayorova. 9th issue. Moscow, 2019. (in Russian).
  12. Duckworth W et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39.
  13. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008; 358 (24): 2630-3.
  14. Бродовская А.Н., Батрак Г.А. Взаимосвязь вариабельности гликемии и поражения почек у больных с впервые выявленным сахарным диабетом 2 типа. Вестн. Ивановской медицинской академии. 2018; 23 (2): 48-9. @@Brodovskaia A.N., Batrak G.A. Vzaimosviaz' variabel'nosti glikemii i porazheniia pochek u bol'nykh s vpervye vyiavlennym sakharnym diabetom 2 tipa. Vestn. Ivanovskoi meditsinskoi aka-demii. 2018; 23 (2): 48-9 (in Russian).
  15. Климонтов В.В., Мякина Н.Е. Вариабельность гликемии при сахарном диабете: инструмент для оценки качества гликемического контроля и риска осложнений. Сахарный диабет. 2014; 17 (2): 190-9. @@Klimontov V.V., Miakina N.E. Variabel'nost' glikemii pri sakharnom diabete: instrument dlia otsenki kache-stva glikemicheskogo kontrolia i riska oslozhnenii. Sakharnyi diabet. 2014; 17 (2): 190-9 (in Russian).
  16. Bailey T et al. Diabetes Sci and Technol 2017; 11 (4): 736-43.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies